Literature DB >> 16287761

Implications of pharmacogenomics for drug development and clinical practice.

Geoffrey S Ginsburg1, Richard P Konstance, Jennifer S Allsbrook, Kevin A Schulman.   

Abstract

Pharmacogenomics is likely to be among the first clinical applications of the Human Genome Project and is certain to have an enormous impact on the clinical practice of medicine. Herein, we discuss the potential implications of pharmacogenomics on the drug development process, including drug safety, productivity, market segmentation, market expansion, differentiation, and personalized health care. We also review 3 challenges facing the translation of pharmacogenomics into clinical practice: dependence on information technology, limited health care financing, and the scientific uncertainty surrounding validation of specific applications of the technology. To our knowledge, there is currently no formal agenda to promote and cultivate innovation, to develop progressive information technology, or to obtain the financing that would be required to advance the use of pharmacogenomic technologies in patient care. Although the potential of these technologies is driving change in the development of clinical sciences, it remains to be seen which health care systems level needs will be addressed.

Entities:  

Mesh:

Year:  2005        PMID: 16287761     DOI: 10.1001/archinte.165.20.2331

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

1.  Aro.

Authors:  David B Nash
Journal:  Biotechnol Healthc       Date:  2006-10

Review 2.  Pharmacogenomics in early-phase clinical development.

Authors:  Tal Burt; Savita Dhillon
Journal:  Pharmacogenomics       Date:  2013-07       Impact factor: 2.533

Review 3.  Drug development in oncology: classical cytotoxics and molecularly targeted agents.

Authors:  Shivaani Kummar; Martin Gutierrez; James H Doroshow; Anthony J Murgo
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

4.  Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.

Authors:  Luis Parodi; Eve Pickering; Laura A Cisar; Doug Lee; Raoudha Soufi-Mahjoubi
Journal:  Arch Drug Inf       Date:  2008-12

Review 5.  Current status of pharmacogenomics testing for anti-tumor drug therapies: approaches to non-melanoma skin cancer.

Authors:  Rebecca Grealy; Lyn R Griffiths
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 6.  A health services research agenda for cellular, molecular and genomic technologies in cancer care.

Authors:  Louise Wideroff; Kathryn A Phillips; Gurvaneet Randhawa; Anita Ambs; Katrina Armstrong; Charles L Bennett; Martin L Brown; Molla S Donaldson; Michele Follen; Sue J Goldie; Robert A Hiatt; Muin J Khoury; Graham Lewis; Howard L McLeod; Margaret Piper; Isaac Powell; Deborah Schrag; Kevin A Schulman; Joan Scott
Journal:  Public Health Genomics       Date:  2009-02-20       Impact factor: 2.000

Review 7.  The evolving role of drug metabolism in drug discovery and development.

Authors:  Lilian G Yengi; Louis Leung; John Kao
Journal:  Pharm Res       Date:  2007-03-01       Impact factor: 4.580

8.  A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine.

Authors:  Kensaku Kawamoto; David F Lobach; Huntington F Willard; Geoffrey S Ginsburg
Journal:  BMC Med Inform Decis Mak       Date:  2009-03-23       Impact factor: 2.796

Review 9.  Translating pharmacogenomics: challenges on the road to the clinic.

Authors:  Jesse J Swen; Tom W Huizinga; Hans Gelderblom; Elisabeth G E de Vries; Willem J J Assendelft; Julia Kirchheiner; Henk-Jan Guchelaar
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.